NRP2 and cervical carcinoma: To offer more evidence of availability as clinical diagnostic tools, it is important to evaluate the miR-331-3p and its target molecules, NRP2 expression using qRT-PCR and immunohistochemistry in cervical cancer and/or dysplasia.